Kardigan

Kardigan is a clinical-stage biopharmaceutical company focused exclusively on cardiovascular medicine. Headquartered in South San Francisco, California, the company describes itself as "a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world." Its stated mission is to develop multiple targeted cardiovascular treatments in parallel, moving beyond symptom management toward what it calls functional cures by addressing the underlying drivers of disease. Kardigan's approach combines a discovery and translational research platform, a pipeline of late-stage clinical candidates, and what the company calls "Cardiac Intelligence" — an integration of real-world patient data, artificial intelligence insights, and deep cardiovascular expertise. The company states that this platform is supported by the integration of Prolaio's AI and real-world data platform, which Kardigan says enhances its ability to generate insights that can inform clinical trial design and potentially reduce the time and cost of development. The company has curated a diverse pipeline with three late-stage clinical programs, each designed to move beyond symptom management. These programs target genetic dilated cardiomyopathy (DCM), a predominantly inherited cardiac muscle disease that impairs the heart's ability to pump blood and carries significant risk of progression to advanced heart failure; calcific aortic valve stenosis (CAVS), caused by calcium deposition that thickens and stiffens the aortic valve and reduces blood flow; and acute severe hypertension (ASH), a sudden and severe spike in blood pressure requiring immediate attention to prevent heart attack, stroke, or organ damage. Kardigan states that collectively these programs create opportunities to generate new clinical insights and data that will fuel ongoing R&D and discovery beyond these three disease areas. Kardigan is led by Co-Founder and CEO Tassos Gianakakos, who has framed the company's strategy around uniting real-world patient data, AI insights, and cardiovascular expertise to advance therapies with the potential to transform outcomes. The company's culture is described as built around a shared passion for working together on behalf of patients and their families. Kardigan has been active as a public company. According to its own press releases, it announced the closing of an initial public offering on June 22, 2026, reported second quarter 2026 financial results and recent business updates on August 11, 2026, and announced that it would present at two September investor conferences on September 2, 2026. Wikidata records the company as located in South San Francisco, United States.

Kardigan is a cardiovascular drug development company based in South San Francisco, California. Public information about the company's earliest corporate history is limited, but its own materials describe an organization built around a single therapeutic focus: cardiovascular disease, which it notes is the leading cause of death in the world. The company's stated purpose is to develop multiple targeted cardiovascular treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve. Kardigan describes itself as having a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team. Its strategy is to create novel medicines that modify the underlying causes of cardiovascular disease, advancing beyond symptom management toward functional cures. A defining element of Kardigan's approach is what it calls "Cardiac Intelligence." The company says it unites real-world patient data, AI insights, and deep cardiovascular expertise to advance therapies with the potential to transform outcomes. Kardigan states that its efforts are supported by the integration of Prolaio's AI and real-world data platform, which it says enhances its ability to generate insights that can inform clinical trial design and potentially reduce the time and cost to develop meaningful therapies. Kardigan has curated a diverse pipeline with three late-stage clinical programs. The first targets genetic dilated cardiomyopathy (DCM), described by the company as a predominantly inherited cardiac muscle disease affecting the heart's main ventricular and atrial chambers, making it difficult to pump blood to the rest of the body and carrying significant risk of progression to advanced stages of heart failure. The second targets calcific aortic valve stenosis (CAVS), the result of calcium deposition leading to thickening and stiffening of the aortic valve and reducing blood flow, thereby impairing cardiac function. The third targets acute severe hypertension (ASH), a sudden and severe spike in blood pressure (systolic blood pressure of 180 mmHg or higher and/or diastolic blood pressure of 110 mmHg or higher) requiring immediate attention to prevent heart attack, stroke, or damage to other organs, and often resulting in hospitalization and organ failure. Kardigan states that collectively these programs create opportunities to generate new clinical insights and data that will fuel its ongoing R&D and discovery efforts beyond these three disease areas. The company is led by Co-Founder and CEO Tassos Gianakakos. In his framing, creating meaningful change for patients suffering from cardiovascular diseases requires thinking differently about how new drugs are developed, and Kardigan aims to unite real-world patient data, AI insights, and deep cardiovascular expertise to advance therapies with transformative potential. The company describes its culture as built around a shared passion for working together on behalf of patients and their families. Kardigan has also been active in the public markets. According to press releases listed on its website, the company announced the closing of an initial public offering on June 22, 2026, reported second quarter 2026 financial results and recent business updates on August 11, 2026, and announced on September 2, 2026 that it would present at two September investor conferences. Wikidata records the company as being located in South San Francisco, United States.

• Kardigan announced the closing of its initial public offering.

• Kardigan reported second quarter 2026 financial results and recent business updates.

• Kardigan announced it would present at two September investor conferences.

A cardiovascular-focused biopharmaceutical company positioning itself around targeted, disease-modifying therapies and an AI/real-world-data-driven "Cardiac Intelligence" platform, aiming to move beyond symptom management toward functional cures.

• Genetic dilated cardiomyopathy (DCM) program

  A late-stage clinical program targeting a predominantly inherited cardiac muscle disease affecting the heart's main ventricular and atrial chambers, making it difficult to pump blood to the rest of the body and carrying significant risk of progression to advanced heart failure.

• Calcific aortic valve stenosis (CAVS) program

  A late-stage clinical program targeting a condition resulting from calcium deposition that thickens and stiffens the aortic valve and reduces blood flow, impairing cardiac function.

• Acute severe hypertension (ASH) program

  A late-stage clinical program targeting a sudden and severe spike in blood pressure (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg) requiring immediate attention to prevent heart attack, stroke, or damage to other organs, and often resulting in hospitalization and organ failure.

1. 1Kardigan | Cardiovascular Drug Development for Heart Healthkardigan.bio
2. 2Kardigan | Cardiac Intelligence for Heart Health | Purposekardigan.bio
3. 3Kardigan - Wikidatawikidata.org